Recent Updates
Recently added Catalysts
CALC Positive Sentiment

CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Tuesday, September 2, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CalciMedica Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. CEO Rachel Leheny will discuss the company's innovative therapies targeting CRAC channels for inflammatory and immunologic diseases. CalciMedica's lead product, Auxora, has shown positive results in clinical trials and is being evaluated in multiple ongoing studies.
Price reaction · baseline $2.7 (2025-08-29 close) · hit pre-market · clean, no other CALC news in the window
day 0 close
+14.8%
day 1 · peak
+19.3%
day 3
+14.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • CalciMedica is participating in a significant investment conference.
  • The company has demonstrated positive clinical results with its lead product candidate Auxora.
  • CalciMedica's therapies target critical inflammatory and immunologic diseases with no current approved treatments.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~12 mo
Medium dilution risk
Lead asset
CM-4620 Injectable Emulsion or CM-4620-IE
Phase 2 · Acute Pancreatitis

Full Press Release Details

LA JOLLA, Calif.,Sept. 2, 2025/PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced thatRachel Leheny, Ph.D., Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference onMonday, September 8, 2025, at3:30 p.m. ET.
A live webcast of the presentation can be accessed in the "IR Events and Presentations" section of CalciMedica's IR website. A replay of the webcast will be archived on the Company's website for 90 days.

About CalciMedicaCalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials and been well-tolerated in over 350 critically ill patients dosed. CalciMedica has announced data for a Phase2btrial (called CARPO –NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and for a Phase 2 trial (called CARDEA –NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE –NCT06374797) in patients with acute kidney injury (AKI) with associated respiratory failure. For more information, please visitwww.calcimedica.com.

Contact InformationKevin Murphyemail protected 600-1902

Frequently Asked Questions

When will CalciMedica present at the conference?

CalciMedica will present on September 8, 2025, at 3:30 p.m. ET.

What is the focus of CalciMedica's therapies?

CalciMedica focuses on developing therapies targeting CRAC channels for inflammatory and immunologic diseases.

What is the status of CalciMedica's lead product candidate?

CalciMedica's lead product candidate, Auxora, has shown positive results in clinical trials.

Where can I access the presentation webcast?

The live webcast can be accessed on CalciMedica's IR website under 'IR Events and Presentations.'

ShareAdd on Google
Tags: CALC Viatris Investor Conferences Healthcare CalciMedica H.C. Wainwright investment conference CRAC channel Auxora
Last updated: Sep 2, 2025

Biotech snapshot

Cash runway
$19M liquidity · $2M/mo burn
~12 mo
Medium dilution risk
Lead asset
CM-4620 Injectable Emulsion or CM-4620-IEPhase 2
Acute Pancreatitis →